C. diff. Spores and More

Join us with our guests;

With Doctor Teena Chopra, MD,MPH,FACP,FIDSA,FSHEA

Associate Professor of Medicine,Division of Infectious Diseases, Corporate Medical Director, Infection Prevention,Epidemiology,and Antibiotic Stewardship ,DMC and WSU Director,Infection Prevention,Epidemiology and Antibiotic Stewardship,Vibra Hospital

Dr. Chopra will lead the discussion with an overview of a C. difficile infection followed by Alba Muhlfeld, and Renata Johnson, C. diff. Survivors both sharing their journey and providing key-points to our global listeners.

Join us with our two guests:

Dr Yannick Pletan, Independent Director Clinical development specialist,Doctor of medicine, and Georges Gaudriault, Scientific Director, PhD in molecular pharmacology.

Both Dr. Pletan and Gaudriault will introduce and discuss

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics, announced the inclusion of the first patient in the Phase II trial testing DNV3837.

DNV3837 targets the treatment of Clostridioides difficile (C. diff. ) infections (CDI), a disease classified as a priority by the WHO and one of the global leading causes of healthcare-related infections*.

DNV3837 is an intravenous antibiotic that, when converted to its active form DNV3681, crosses the gastrointestinal barrier and accumulates in the intestinal lumen, allowing it to precisely target the infection site.

Join us with our two guests:

Dr Yannick Pletan, Independent Director Clinical development specialist,Doctor of medicine, and Georges Gaudriault, Scientific Director, PhD in molecular pharmacology.

Both Dr. Pletan and Gaudriault will introduce and discuss

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-based active ingredients for cosmetics, announced the inclusion of the first patient in the Phase II trial testing DNV3837.

DNV3837 targets the treatment of Clostridioides difficile (C. diff. ) infections (CDI), a disease classified as a priority by the WHO and one of the global leading causes of healthcare-related infections*.

DNV3837 is an intravenous antibiotic that, when converted to its active form DNV3681, crosses the gastrointestinal barrier and accumulates in the intestinal lumen, allowing it to precisely target the infection site.

PART II

The 2019–20 coronavirus pandemic is a pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in Wuhan, Hubei, China in December 2019. Join Our Guest: Maureen Spencer, RN, M.Ed, CIC, will be joining us to continue discussing the coronavirus (COVID-19) through Prevention, Symptoms, and the global healthcare focus.

The 2019–20 coronavirus pandemic is a pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in Wuhan, Hubei, China in December 2019.

Join Our Guest: Maureen Spencer, RN, M.Ed, CIC, who

will be discussing the coronavirus

(COVID-19) an introduction through

Prevention, Symptoms, and the global healthcare focus.

Join us with guests: Leigh Veasey, Sales Director - North America and Wendy Brady, Marketing Director - North America of Intellego Technologies.

Both guests will be discussing UVC disinfecting, the use of UVC the use of dosimeter indicators in the healthcare environment.

Learn more about dosimeter indicators, verification to ensure that UVC disinfection and devices are reaching their intended targets.

Infection Prevention data shared that you will not want to miss!

Join us with guests: Leigh Veasey, Sales Director - North America and Wendy Brady, Marketing Director - North America of Intellego Technologies.

Both guests will be discussing UVC disinfecting, the use of UVC the use of dosimeter indicators in the healthcare environment.

Learn more about dosimeter indicators, verification to ensure that UVC disinfection and devices are reaching their intended targets.

Infection Prevention data shared that you will not want to miss!

The 2019–20 coronavirus pandemic is a pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in Wuhan, Hubei, China in December 2019. Join us with our guests, Dr. Teena Chopra, MD, MPH and Jennifer Wood, a C. diff. Survivor as we introduce the COVID-19, compare and contrast the precautions, treatments, and environmental safety for both infectious diseases.

Join us as guests Sue Barnes, RN, BSN, CIC, FAPIC, Independent and Board Certified Clinical Consultant in Infection Control and Prevention and APIC Fellow with Lori Strazdas, MPH - Public Health Liaison with Clorox Healthcare discuss the importance of C. difficile and how difficult of an infection it is to manage not only for patients but for the caretakers and loved ones. Before the patient leaves the hospitals, it is critical to understand the proper steps to reduce the spread of C. difficile spores in the home environment. In this episode, learn why it is important to focus on the home environment during and after a C. difficile infection and what can be done to reduce the risk of transmission and recurrence. Our guests will be discussing the types of disinfecting products that can be utilized to effectively kill C. diff. spores and how to use the products properly to accomplish this in the home environment.

Join us with our guest: Mrs. Courtney Jones, Upstream Marketing Manager and Senior Project Manager at Rebiotix, a Ferring Pharmaceuticals company, focused on harnessing the power of the human microbiome to treat debilitating diseases. Mrs. Jones will be discussing and explaining the Microbiome. What Microbes are and the difference between the good, bad, and in between and what the Microbiome has to do with C.diff. treatment. There is a lot to learn about the science of the Microbiome and Mrs. Jones will certainly be educating us on this episode.